The B-FAST trial (NCT 03178552) is an ongoing phase II/III study enrolling patients with advanced NSCLC harboring actionable somatic mutations in the blood, with cohort E being patients with BRAF V600E mutations and treated with vemurafenib, cobimetinib and atezolizumab. This evidence concerns the gene BRAF and non-small cell lung carcinoma.